C to U RNA editing is catalyzed by a multicomponent holoenzyme containing a single catalytic subunit, apobec-1. We have characterized an apobec-1 homologue, ARCD-1, located on chromosome 6p21.1, and determined its role in apoB mRNA editing. ARCD-1 mRNA is ubiquitously expressed; phylogenetic analysis reveals it to be a distant member of the RNA editing family. Recombinant ARCD-1 demonstrates cytidine deaminase and apoB RNA binding activity but does not catalyze C to U RNA editing, either in vitro or in vivo. Although not competent itself to mediate deamination of apoB mRNA, ARCD-1 inhibits apobec-1-mediated C to U RNA editing. ARCD-1 interacts and heterodimerizes with both apobec-1 and apobec-1 complementation factor (ACF) and localizes to both the nucleus and cytoplasm of transfected cells. Together, the data suggest that ARCD-1 is a novel cytidine deaminase that interacts with apobec-1 and ACF to inhibit apoB mRNA editing, possibly through interaction with other protein components of the apoB RNA editing holoenzyme. gene cluster; immunofluorescence; protein-protein interaction; RNA-protein interaction
gene cluster; immunofluorescence; protein-protein interaction; RNA-protein interaction APOLIPOPROTEIN B (apoB), the major protein component of triglyceride-rich lipoprotein particles, is present in two forms, apoB100 and apoB48, each the product of a common structural gene (reviewed in Ref. 41 ). ApoB100, generated in the human liver, is present on very low density and low-density lipoprotein particles. However, in the mammalian intestine and liver of some species, the genomically templated apoB mRNA undergoes a single posttranscriptional C to U RNA editing event, creating a premature stop codon (8, 31) . Translation of the edited mRNA results in the formation of apoB48, which is a component of chylomicron particles (8, 31) . Accordingly, C to U editing of apoB mRNA plays a major role in the formation and resulting metabolism of apoB-containing plasma lipoproteins (reviewed in Ref. 2) .
ApoB mRNA editing is catalyzed by a multicomponent enzyme complex, referred to as an editosome (2, 33) . The complex contains a minimal functional core, comprising two proteins, apobec-1 and a required complementation factor, ACF (21, 26, 36) . Apobec-1 is a 27-kDa RNA-specific cytidine deaminase that binds to the apoB RNA substrate and catalyzes a site-specific C to U deamination reaction in the nuclear transcript (3, 29, 36) . In humans, apobec-1 is expressed exclusively in the luminal gastrointestinal tract, but in certain species, including rodents, its expression is more widespread (10, 13, 20, 28, 38) . Apobec-1 is a zinc-dependent enzyme that exhibits considerable homology to other members of the cytidine deaminase family, particularly in its catalytic domain (30) . The catalytic domain contains a histidine and glutamate residue in one alpha helix and a pair of cysteine residues in a second, closely opposed helix that function to coordinate a molecule of zinc in a tetrahedral configuration (30) . Based on the crystal structure of Escherichia coli cytidine deaminase, a model for apobec-1 has been proposed that predicts a head-to-tail orientation of two apobec-1 monomers that are organized as a functional homodimer and thereby enable the glutamate residue to function as a proton donor in the deamination reaction while simultaneously permitting docking of the protein onto the apoB RNA template (30) . Apobec-1 is an RNA-binding protein that interacts with the hexamer sequence UUUGAU, which is located immediately downstream of the edited base in apoB RNA (1) . RNase mapping and computer modeling studies have demonstrated the presence of a stem-loop structure for apoB RNA with the edited base in the terminal loop, a structure that is favorable for the binding and editing by apobec-1 (1, 14, 32) .
These characteristics of apobec-1 suggest a series of complex adaptations that have evolved to permit the exquisite site-specific deamination of a single cytidine in an RNA template of over 14,000 nt. These suggestions, coupled with the widespread distribution of apo-bec-1 mRNA in rodent tissues and its relatively recent emergence as an RNA-specific deaminase (4) , imply that other related cytidine deaminases may exist whose structure and function may be informative with regard to the adaptations alluded to above. Accordingly, we utilized a functional gene database screening approach to identify apobec-1-like proteins. This led us to identify a family of cytidine deaminases with significant homology to apobec-1 in the catalytic domain, suggesting that these proteins are likely to act as RNA editing proteins.
In the current paper, we report the characterization of one of the novel cytidine deaminase, referred to as ARCD-1, encoded on chromosome 6p21.1. ARCD-1 is ubiquitously expressed and has a cytidine deaminase activity of high specificity. The protein localizes to both nucleus and cytoplasm in transfected cells. ARCD-1 demonstrates significant homology to apobec-1 and binds to apoB RNA but does not catalyze apoB RNA editing. However, ARCD-1 inhibits apoB RNA editing in a dose-dependent manner and reveals protein-protein interactions with apobec-1 and with ACF. Together, these data suggest that ARCD-1 is a ubiquitously expressed novel cytidine deaminase that may act as a dominant negative inhibitor of apoB RNA editing by interacting with apobec-1 and/or ACF.
MATERIALS AND METHODS
Cloning and tissue distribution of ARCD-1. ARCD-1 was cloned from adult human small intestinal RNA by RT-PCR using primers VSARCD-1 (5Ј-ATG GCC CAG AAG GAA GAG GCT GCT GTG G-3Ј) and VSARCD-2 (5Ј-CTA CTT AAG GAT GTC TGC CAA CTT CTC CTC GTA GTA-3Ј). The PCR products were cloned into the pPCR-SCRIPT SK(ϩ) amp cloning vector (Stratagene, La Jolla, CA), and both strands were sequenced. Full-length antisense ARCD-1 riboprobe was generated in the presence of [␣-
32 P]UTP (3,000 Ci/mmol) and used to probe a human multiple-tissue Northern blot (Clontech, Palo Alto, CA) with ExpressHyb hybridization solution (Clontech) according to the manufacturer's instructions. A PCR-based approach for assessing gene expression was performed with a human and a mouse Rapid Scan Gene Expression Panel (Origene Technologies, Rockville, MD) with primers VSARCD-1 and VSARCD-2. Control primers for the amplification of ␤-actin cDNA were supplied by Origene Technologies. Sequence analysis was conducted using the Clustal W sequence alignment program in the MacVector 6.5 package (Oxford Molecular Group, Campbell, CA). The presence of the same amino acid at any given position is defined as "identity," while a conserved change in the amino acid is represented as "similarity." The similarity matrix used for determining amino acid identity and similarity was Blosum 30 (MacVector). The pairwise alignment parameters were an open gap penalty of 10 and an extended gap penalty of 0.1.
Recombinant ARCD-1, apobec-1, and ACF expression. ARCD-1 was subcloned into the bacterial expression vector pThioHisC (Invitrogen, Carlsbad, CA), at BamHI and XhoI sites, after PCR amplification with Pwo polymerase by using primers SA150 (5Ј-GAC GAC GAC AGG GGA TCC ATG GCC CAG AAG GAA GAG GCT GCT GTG G-3Ј; BamHI site underlined) and VS21 (5Ј-GGG CTC GAG CTA CTT AAG GAT GTC TGC CAA CTT CTC CTC GTA GTA-3Ј; XhoI site underlined) and sequenced on both strands. Expression and purification of the recombinant protein by nickel-affinity chromatography using a ProBond resin (Invitrogen) was performed according to the manufacturer's instructions. Apobec-1 was expressed as a glutathione-S-transferase (GST) fusion protein as previously described (23) . ACF cDNA, isolated from human liver RNA using primers ACF1 (5Ј-GGA TCC CCA TAT GGA ATC AAA TCA CAA ATC CG-3Ј; BamHI restriction site underlined) and ACF2 (5Ј-CTC GAG TCA GAA GGT GCC ATA TCC ATC-3Ј; XhoI restriction site underlined), was cloned into plasmid PET-28a (Novagen, Madison, WI) at the BamHI and XhoI sites and expressed as histidine (His)-tagged protein. Protein expression was performed according to the manufacturers' recommendations (Amersham Pharmacia Biotech, Piscataway, NJ; Novagen). The proteins were size fractionated on 12% SDS-PAGE and silver stained. The purity of pThioHisC-ARCD-1, GST-apobec-1, and His-ACF was determined to be 99, 70, and 99%, respectively. In vitro apoB RNA editing and primer extension analyses were performed as previously described (23) . The products of the primer extension analyses were separated on an 8% urea-PAGE gel and subjected to phosphorimaging analysis. Stably transfected rat hepatoma cells (McArdle7777) were generated by selection with 800 g/ml G418 after transfection with plasmids pCMV4-apobec-1 and pCMV-neo, as previously described (23) .
Cytidine deaminase activity of recombinant ARCD-1. Increasing concentrations of recombinant ThioHis-ARCD-1 (1-500 ng) were incubated with [ 3 H]deoxycytidine in a buffer containing 45 mM Tris (pH 7.5) and 250 M unlabeled cytidine for 4 h at 37°C. The reaction mix was subjected to thin-layer chromatography on polyethyleneimine-cellulose. Bands corresponding to deoxycytidine and deoxyuridine were excised, and radioactivity was counted in a beta counter (Beckman Coulter, Fullerton, CA). Where indicated, inhibitors of cytidine deaminase activity, tetrahydrouridine (1-40 M) and 1,10-o-phenanthroline or its inactive isomer, 1.7-ophenanthroline (5-25 M), were added to the reaction mix.
Generation of recombinant adenovirus expressing ARCD-1. Full-length ARCD-1 with a COOH-terminal FLAG epitope tag was cloned in pAxCAwt adenoviral vector (PanVera, Madison, WI), at the SwaI restriction endonuclease site, for expression under the control of the chicken ␤-actin promoter. This vector was used to generate recombinant adenovirus in 293 cells according to the manufacturer's instructions. Viral titers were obtained with a multiplicity of infection (MOI) of 10 9 -10 10 plaque-forming units/ml. McArdle7777 cells were infected with increasing titers (2-4 ϫ 10 3 MOI) of either recombinant adenovirus expressing ARCD-1 or the bacterial ␤-galactosidase and were incubated for 48 h. Total RNA and cell lysates were prepared as described previously (23) and used for primer extension and Western blot analyses.
Western and Far Western analyses. Anti-ARCD-1 antibody was generated in rabbits to a synthetic peptide corresponding to amino acids 206-224 (EDIQENFLYYEEKLADILK; Research Genetics, Huntsville, AL), and IgG was purified by Affi-gel Protein A chromatography (Bio-Rad, Hercules, CA) according to the manufacturer's instructions. Antibodies generated against apobec-1 have been described previously (23) . Western blot analysis was performed for detection of recombinant GST-apobec-1 or ARCD-1, followed by detection with enhanced chemiluminescence (Amersham Pharmacia Biotech). For Far Western analysis, 1 g of recombinant ThioHis-ARCD-1 was separated on 12% SDS-PAGE and blotted onto Immobilon P membrane (Millipore, Bedford, MA). The immobilized protein was denatured with 6 M guanidine hydrochloride in buffer A [20 mM HEPES, pH 7.9, 100 mM KCl, 0.2. mM EDTA, 20% glycerol, 0.5 mM dithiothreitol (DTT), 0.5 mM phenylmethylsulfonyl fluoride (PMSF), and 0.5 mM benzamidine] at room temperature for 1 h. Proteins were renatured by incubation with serial dilutions of the denaturation buffer (17, 26) . The membrane was blocked overnight at 4°C with 5% BSA and 5% skim milk in buffer A, followed by incubation with 35 S-labeled apobec-1 (5 ϫ 10 5 cpm/ml) in buffer B (buffer A plus 2.5 mM MgCl 2, 0.5% skim milk, 2% BSA, and 0.1% Tween 20) for 16 h at 30°C. The filters were washed three times in buffer C (buffer A plus 2.5 mM MgCl 2 and 0.1% Tween 20), dried at room temperature, and analyzed by autoradiography.
Coimmunoprecipitation assays. ARCD-1 was cloned into the plasmid pCMV-Tag3B (Stratagene), at BamHI and XhoI sites, for expression as an NH 2-terminal c-myc-tagged fusion protein. Cloning of ACF in plasmid pCMV-Tag2B has been published previously (7) . pCMV-Tag3B-ARCD-1 (NH 2-terminal c-myc-tagged) and pCMV-Tag2B-ACF (NH2-terminal FLAG-tagged) were transcribed and translated in vitro using TNT rabbit reticulocyte lysate system (Promega, Madison, WI) with T3 RNA polymerase. The lysates were mixed and incubated at 30°C for 30 min in a binding buffer (20 mM HEPES pH 7.9, 100 mM KCl, 1 mM EDTA, 10% glycerol, 1 mM PMSF, and 0.4% Nonidet P-40). Immunoprecipitations were subsequently performed for either the FLAG or myc tags by using a mouse anti-FLAG monoclonal antibody (Stratagene) or a mouse anti-myc monoclonal antibody 9E10 (Santa Cruz Biotechnology, Santa Cruz, CA), respectively. The immunoprecipitates were fractionated on 12% SDS-PAGE and analyzed by autoradiography.
Immunofluorescence studies. HepG2, McArdle7777, and COS-7 cells, grown on cover glass, were transiently transfected with pCMV3B-ARCD-1 by using FUGENE (BoehringerMannheim) and were incubated for 48 h. The slides were fixed with 0.5% formaldehyde, permeabilized with 0.5% Triton X-100, and probed with mouse ␣-c-myc monoclonal antibody (Santa Cruz), followed by Cy3-conjugated affinity-purified donkey anti-mouse antibody (Jackson ImmunoResearch Laboratories, West Grove, PA). Stained cells were mounted with Vectashield (Vector Laboratories, Burlingame, CA), and nuclei were imaged with 4,6-diamidino-2-phenylindole (DAPI). Images were obtained with the use of a Zeiss Axiostop 2 MOT microscope equipped with a ϫ40 plan-neofluor objective and a 3CCR camera (DAGE-MTI, Michigan City, IN). A Zeiss Attoarc variable-intensity lamp was used with filters designed for Cy3 and DAPI. The images were processed using Adobe Photoshop 4.0 software.
Ultraviolet cross-linking and electrophoretic mobility shift assays. A 32 P-labeled rat apoB mRNA template, RB105 (50,000 cpm at 4 ϫ 10 8 cpm/g) (3), was incubated with indicated amounts of purified recombinant ThioHis-ARCD-1 and/or GST-apobec-1 for 15 min at room temperature in a binding buffer containing 10 mM HEPES (pH 8.0), 100 mM KCl, 1 mM EDTA, 0.25 mM DTT, and 2.5% glycerol. The RNA was then sequentially treated with RNase T1 (1 U/l final concentration) and heparin (5 mg/ml final concentration). For electric mobility shift assay (EMSA) analysis, the reaction mixtures were fractionated in a 5% native PAGE and autoradiographed. For competition analysis with either wild-type or mutant apoB RNAs, a 100-fold excess of competitor was used in the reaction. For ultraviolet (UV) crosslinking analysis, the reaction mixture was further subjected to UV cross-linking in a Stratalinker (Stratagene) at 250 mJ/cm 2 and subsequently analyzed by 12% SDS-PAGE under denaturing conditions.
RESULTS AND DISCUSSION
Cloning and comparative analysis of ARCD-1. A search of the National Center for Biotechnology Information's human expressed sequence tag (EST) database for apobec-1-like cytidine deaminases containing the conserved signature sequence (H/C)-(A/V)-E-(X) [24] [25] [26] [27] [28] [29] [30] -P-C-(X) 2 -C revealed the presence of activation-induced deaminase (AID) (27) , phorbolin (24) , and seven novel transcripts, herein referred to as apobec-1-related cytidine deaminases (ARCD-1 to -7) (Fig. 1A) . On the basis of a search of human genomic sequences (http://www.ncbi.nlm. nih.gov), ARCD-1 is located on chromosome 6p21.1 (BAC clone 18464), whereas ARCD-2 to -7 are clustered on chromosome 22q12-13.2 (BAC clone bk150C2). Comparative analysis of residues spanning the putative catalytic domain of the ARCD members with the known cytidine and deoxycytidine deaminases, using the distance mapping program PROTDIST (4, 9) , suggests that the ARCDs cluster with AID and phorbolin (24, 27) and represent a distant evolutionary branch of the RNA editing enzyme apobec-1 (Fig. 1B) . These results suggest that proteins containing the characteristic cytidine deaminase active site domain appear similar to the RNA editing enzyme apobec-1 and are encoded in chromosomes 6 and 22. The functional significance of ARCD-1 in C to U editing of apoB RNA was further investigated.
Tissue distribution of ARCD-1. GenBank database searches had earlier revealed ARCD-1 ESTs in skeletal and cardiac muscle, small intestine, colon, liver, and kidney (data not shown). To further resolve the distribution of ARCD-1 mRNA, we probed a human multipletissue RNA blot with the full-length ARCD-1 antisense riboprobe. Similar to the Blast search data, moderate to abundant expression was observed in kidney, liver, and small intestine, as well as high levels of expression in cardiac and skeletal muscle ( Fig. 2A) . These latter findings are consistent with the recent report of Liao et al. (22) . The presence of a doublet in cardiac and skeletal muscle RNA suggests that alternate forms of ARCD-1 mRNA are transcribed. This may represent differences in the 5Ј and/or 3Ј untranslated regions, since RT-PCR of the full-length coding region consistently demonstrated a single product (Fig. 2B) . Moreover, with a more sensitive PCR analysis of a multipletissue cDNA panel, ARCD-1 expression was observed to be ubiquitous in both human and mouse tissues (Fig. 2B) . ARCD-1 mRNA also was detectable in early embryonic mouse tissue, as early as E8.5 (Fig. 2B) .
Functional analysis of ARCD-1. Full-length ARCD-1 cDNA is 673 bp long and encodes a protein of 224 amino acids with a predicted molecular weight of 25 kDa (Fig. 3A) . Scanning the ARCD-1 protein sequence against the Pfam database (http://pfam.wustl.edu/) demonstrated the presence of the active site zinc-binding domain between amino acids 98 and 131 (Fig. 3A) (5). The human ARCD-1 gene, encoded in BAC clone 18464 spans ϳ11 kb and contains three exons, including an untranslated exon 3 ( Fig. 3B and Table 1 ). The catalytic domain is located within the second exon (Fig.  3B) . This genomic organization is distinct from that The catalytic domain of cytosine nucleotide and nucleoside deaminases, blasticidin-S deaminase, the RNA editing enzymes, and novel apobec-1-related cytidine deaminases (ARCD-1 to -7) were aligned on the basis of the crystal structure of the Escherichia coli cytidine deaminase (6). The zinc-coordinating residues are indicated by arrows, and the glutamate residues, which are the proton donors in the deaminase reaction, are indicated by arrowheads. B: phylogenetic analysis of ARCDs. The catalytic domain, shown in A, was used to generate a distance matrix using the PROTDIST program (9) . A tree was subsequently generated using the KITSCH program and plotted using the DRAWTREE program.
previously observed with apobec-1 (15, 16, 28) . The apobec-1 coding region is encoded in five exons, with the catalytic domain located within exon 3 (15, 16, 28) . Alignment of the primary amino acid sequences of ARCD-1 and apobec-1 demonstrates significant homology between each of these sequences (Fig. 3B and Table  2 ), as well as with E. coli cytidine deaminase (Table 2) . Whether apobec-1 and ARCD-1 arose from a common ancestral gene remains unanswered.
ARCD-1 is a cytidine deaminase. ARCD-1 was expressed as a fusion protein with a ThioHis tag and was purified under native conditions by nickel-affinity chromatography. SDS-PAGE analysis of the purified fusion protein revealed a single prominent polypeptide of an apparent size of ϳ35 kDa, although the predicted size is ϳ31 kDa (Fig. 4A) . Cytidine deaminase assay revealed that the enzymatic activity of ThioHis-ARCD-1 increased in a dose-dependent manner (Fig.   Fig. 2 . Tissue distribution of ARCD-1. A: Northern blot analysis. A human multiple-tissue Northern blot was probed sequentially with riboprobes for human ARCD-1 and ␤-actin and subjected to autoradiography. Location of the ARCD-1 and ␤-actin mRNAs are shown (right), and migration of known molecular weight markers are shown (left). B: PCR analysis for ARCD-1 expression. Multiple-tissue cDNA panels from human and mouse tissue were subjected to PCR with ARCD-1-and ␤-actin-specific primers. The products of the PCR were analyzed by 1% agarose gel electrophoresis. Tissues in both the blot (A) and PCR (B) panels include brain (B), heart (H), skeletal muscle (SM), stomach (St), colon (C), testis (T), spleen (Sp), kidney (K), liver (L), small intestine (SI), pancreas (P), lung (Lu), skin (Sk), placenta (Pl), salivary gland (SG), thyroid gland (Tg), adrenal gland (Ad), ovary (O), uterus (U), prostate (Pr), bone marrow (BM), fetal brain (FB), fetal liver (FL), peripheral blood leukocytes (PB), and mouse breast samples including virgin (V), pregnant (P), lactating (L), and involuting breast (I). 4B) and was inhibited upon addition of excess unlabeled cytidine or deoxycytidine (data not shown). Furthermore, the activity was linear with respect to protein concentration and time, up to 150 ng (Fig. 4B ) and 60 min (data not shown), respectively. The MichaelisMenten constant and maximal velocity for ARCD-1 were determined to be 1 ϫ 10 Ϫ5 M and 4.8 U/mg protein, respectively, which are comparable to those observed with other cytidine deaminases, including those isolated from Caenorhabditis elegans and Brugia pahangi as well as apobec-1 and a related homologue, AID (Table 3) . Cytidine deaminase activity was inhibited in a dose-dependent manner upon the inclusion of either 1,10-o-phenanthroline (Fig. 4C ) or tetrahydrouridine (Fig. 4D) . However, addition of 1,7-ophenanthroline, an inactive isomer that does not chelate zinc, had no effect on the activity (Fig. 4C ). These data demonstrate that ARCD-1 functions as an authentic, zinc-dependent cytidine deaminase.
ARCD-1 is an ApoB RNA-binding protein.
Previous studies have demonstrated that RNA binding activity is essential for apobec-1 to catalyze C to U editing of apoB RNA (23, 29) . Apobec-1 is an AU-rich RNAbinding protein with affinity for a hexanucleotide sequence, located immediately downstream of the edited base (1). In addition, mutagenesis studies have identi- fied two aromatic residues within the catalytic domain of apobec-1 that are essential for RNA binding (29, 37) . On the basis of the protein sequence alignment of apobec-1 and ARCD-1, we observed that these aromatic residues are conserved in ARCD-1, implying that it also might be an RNA-binding protein (Fig. 3B) . Accordingly, EMSAs were performed with purified recombinant ARCD-1 and 32 P-labeled wild-type apoB mRNA. As shown in Fig. 5A , ARCD-1 bound apoB RNA, which was supershifted when apobec-1 was also added to the reaction (Fig. 5A) . To further determine the binding specificity, we performed EMSA analysis with radiolabeled human apoB RNA in the presence of cold apoB transcripts of the same size into which two different scrambled 6-nt mutations had been introduced (Fig. 5B , mutants C and D) (32) . Mutant D was especially chosen for the experiment because it contains part of the apobec-1 binding site (1) . In addition, tRNA was added as competitor because previous studies from our laboratory have demonstrated that tRNA inhibits apobec-1 binding to apoB RNA (3) . Both of the apoB RNA scrambling mutants inhibited ARCD-1 binding, suggesting that ARCD-1 and apobec-1 may bind to different sites in apoB RNA. In UV crosslinking assays, both ARCD-1 and apobec-1 demonstrated cross-linking to apoB RNA (Fig. 5C ). It should be noted that the difference in size of the cross-linked bands in Fig. 5C reflects the size of the respective fusion proteins (MATERIALS AND METHODS). No competition for binding was observed between the two proteins when they were added simultaneously to the radiolabeled transcript (Fig. 5C ), again suggesting, among other possibilities, that ARCD-1 and apobec-1 may bind to different sites in apoB RNA. On the basis of the intensity of the ARCD-1 band in both the UV crosslinking and EMSA analyses, we speculate that the binding affinity of ARCD-1 for apoB RNA is lower than that of apobec-1. The finding that apoB RNA binding is also abrogated in the presence of 100-200 ng of tRNA (Fig. 5B ) further suggests that this interaction is of low specificity. Further study of this issue, however, will require fine mapping of the binding site coupled with kinetic measurements of RNA-binding affinity before such speculation can be formally tested.
ARCD-1 inhibits apoB mRNA editing both in vitro and in vivo.
The observation that ARCD-1 is a cytidine deaminase and an apoB RNA-binding protein raised the possibility that it might either substitute for apobec-1 in editing apoB RNA or modulate the editing process. Accordingly, recombinant ARCD-1 was analyzed for its ability to catalyze in vitro apoB mRNA editing, as previously described (23) . Increasing amounts (0-500 ng) of ARCD-1, added to bovine liver S-100 extracts, failed to catalyze C to U editing of apoB RNA, suggesting that ARCD-1 cannot substitute for apobec-1 in the editing reaction (Fig. 6A, lane 3 , and data not shown). However, the addition of increasing quantities of recombinant ARCD-1 to assays containing 250 ng of GST-apobec-1 and bovine liver S-100 extracts demonstrated competitive inhibition of apoB RNA editing, with complete inhibition observed upon addition of 300 ng of ARCD-1 (Fig. 6A) . We previously demonstrated that the addition of up to 2 g of other apoB RNA-binding proteins, including hnRNP-A1, hnRNP-F, and hnRNP-I/PTB, fails to modulate C to U Fig. 6 . ARCD-1 inhibits apoB mRNA editing. A: in vitro RNA editing. Increasing amounts of ARCD-1 (0-500 ng) were added to assays containing 20 fmol of apoB RNA, 250 ng of GST-apobec-1, and 10 g of 30% ammonium sulfate precipitate of bovine liver S-100 (Bov Liv S100) extracts. The RNA was extracted and C to U editing quantitated by primer extension analysis. As control, 250 ng of ARCD-1 were added to an assay containing GSTapobec-1 and apoB RNA but no S-100 extracts. Edited RNA was quantitated by phosphorimaging. Data are representative of 3 such experiments. B: endogenous apoB mRNA editing. McArdle7777 cells, a rat hepatoma cell line, were stably transfected with apobec-1, and individual clones were selected that demonstrated 85-90% endogenous apoB mRNA editing. These cells were infected with increasing multiplicity of infection (2-4 ϫ 10 3 MOI) of a replication-defective recombinant adenovirus encoding either ␤-galactosidase (LacZ) or FLAG-tagged ARCD-1. Lysates were subjected to Western blot analysis with ␣-FLAG antibody (WB:␣-FLAG) to detect expression of exogenous ARCD-1 (top). In addition, total RNA from the cells was isolated and used as a template for RT-PCR to amplify apoB RNA sequences around the edited site. The RT-PCR products were subsequently subjected to primer extension analysis to quantitate C to U editing. ApoB mRNA editing was quantitated by phosphorimaging analysis and represented as a percentage of control (bottom). Data are representative of 3 such experiments.
editing of apoB RNA in this assay (7) . We conclude that the inhibition observed with ARCD-1 is therefore not a general phenomenon observed with the addition of AU-rich RNA-binding proteins.
To pursue this inhibition of C to U RNA editing and to determine whether ARCD-1 exerts inhibitory activity in vivo, we generated a replication-defective adenovirus expressing either the bacterial LacZ protein or FLAG-tagged ARCD-1. Preliminary studies were undertaken with McArdle7777 cells, a rat hepatoma cell line that edits ϳ10-15% endogenous apoB RNA (7) . Transduction of McArdle7777 cells with the adenovirus encoding ARCD-1 reduced C to U editing to undetectable levels (data not shown). Nevertheless, because viral toxicity and the low levels of endogenous apoB RNA editing could contribute to this effect, a more stringent approach was sought to address the question of whether ARCD-1 could inhibit apobec-1-mediated C to U editing. The recombinant virus was therefore transduced into McArdle7777 cells stably transfected with apobec-1, which demonstrate ϳ85-90% apoB mRNA editing (Fig. 6B) , the result of overexpression of apobec-1 (23) . As demonstrated in Fig. 6B , endogenous apoB mRNA editing was inhibited by ARCD-1 in a dose-dependent manner, whereas no effect on RNA editing was observed when the cells were infected a recombinant virus expressing ␤-galactosidase. These results confirm the findings from the in vitro studies suggesting that ARCD-1 inhibits apoB mRNA editing catalyzed by apobec-1.
Protein-protein interaction of ARCD-1 with apobec-1 and with ACF. Apobec-1 has been shown to bind to a number of candidate editosomal proteins, including ACF, GRY-RBP, ABBP-1, and hnRNP-C (7, 12, 19, 21, 26) . Some of these, including GRY-RBP, ABBP-1, and hnRNP-C, have been demonstrated to inhibit apoB RNA editing (7, 12, 19) . Because ARCD-1 inhibited C to U RNA editing activity, we reasoned that it might interact with key components of the editing holoenzyme, including apobec-1 and ACF. To address this question, we evaluated protein-protein interaction between ARCD-1 and apobec-1 by Far Western analysis. Recombinant ThioHis-ARCD-1 and GST-apobec-1 were resolved by SDS-PAGE, transferred to polyvinylidene difluoride membranes, and incubated with 35 Slabeled apobec-1. The results, shown in Fig. 7A , demonstrate heterodimerization between apobec-1 and ARCD-1, suggesting that apobec-1 and ARCD-1 can associate in the absence of apoB RNA. By way of control, homodimerization of apobec-1 was confirmed in this assay as previously reported (7, 18, 26) . The migration of apobec-1 and ARCD-1 was confirmed by Western blotting with ␣-apobec-1 and ␣-ARCD-1 antibodies, respectively (Fig. 7A ).
To further demonstrate interaction between ARCD-1 and ACF, we undertook immunoprecipitation analysis of radiolabeled in vitro translation products. In vitrotranslated myc-tagged ACF yielded a predominant species of ϳ67 kDa, as described previously (7), whereas that of FLAG-tagged ARCD-1 yielded a protein of ϳ26 kDa (Fig. 7B) . Mixing the proteins and immunoprecipitating with either ␣-FLAG or ␣-myc antibodies revealed the presence of both proteins, suggesting that ARCD-1 and ACF are present as heteromers in solution. Control immunoprecipitations, performed with radiolabeled ligand and anti-epitope antibody in the absence of its cognate protein, revealed no product (Fig. 7B) .
Immunolocalization of ARCD-1 in transfected cells. ApoB mRNA editing is a nuclear event that occurs either during or after mRNA splicing (18, 35) . Recent studies have demonstrated that apobec-1 is present in both the nucleus and cytoplasm, suggesting that its Fig. 7 . ARCD-1 interacts with apobec-1 and apobec-1 complementation factor (ACF). A: recombinant GST-apobec-1 and ThioHis-ARCD-1 were separated on 12% SDS-PAGE and subjected to Western blot (WB) analysis with ␣-apobec-1 and ␣-ARCD-1 IgG. Subsequently, the membrane was subjected to Far Western analysis (FW) with 35 S-labeled apobec-1 and then autoradiographed. Locations of the bands corresponding to apobec-1 and ARCD-1 are indicated (right), and molecular mass markers (kDa) are shown (left). B: myc-ARCD-1 and FLAG-ACF were generated in vitro by using a coupled 2,4,6-trinitrotoluene lysate in the presence of [ 35 S]methionine, resulting in the production of a single major product for the two proteins (lanes 1 and 2) . The products were mixed and subjected to immunoprecipitation (IP) with either ␣-FLAG (␣-F; lane 3) or ␣-myc (␣-m; lane 4) antibodies. Mobility of the 2 species is indicated (right), with molecular mass markers (kDa) indicated (left). function may reflect shuttling between these compartments. (7, 40) . Mutagenesis studies identified a bipartite nuclear localization and leucine-rich nuclear export signal sequences in the NH-2 and COOH terminus of apobec-1, respectively (40) . Similarly, human cytidine deaminase was found to contain a bipartite nuclear localization signal, and cytidine deaminase was observed in both compartments of the cell (34) . A search of the predicted ARCD-1 sequence did not reveal the presence of any known nuclear import or export sequences (data not shown), and the conserved nuclear localization sequence in apobec-1 was not present in ARCD-1. To determine the intracellular localization of ARCD-1, we introduced FLAG-tagged ARCD-1 into COS-7, HepG2, and McArdle7777 cells. These three cell lines were chosen to reflect intrinsic differences in the expression of apoB RNA and the transacting proteins required for C to U RNA editing. Specifically, COS-7 cells do not express apoB RNA or the editing factors apobec-1 and ACF (7, 26, 40) . HepG2 cells express endogenous apoB RNA and ACF but not apobec-1 (7, 11) . McArdle7777 cells, on the other hand, express endogenous apoB RNA, apobec-1, and ACF and support C to U editing activity (7, 25, 26, 39) . Indirect immunofluorescence staining of the transfected cells for the FLAG epitope demonstrated diffuse nuclear and cytoplasmic ARCD-1 staining in all three cell lines (Fig. 8) , a pattern of distribution similar to that observed with apobec-1 (40) . These data suggest that the cellular distribution of ARCD-1 is neither dependent on nor apparently influenced by the expression of either of ACF, apobec-1, or the target substrate RNA. Attempts to localize the endogenous protein by using either anti-peptide antisera or affinity-purified IgG were unsuccessful, suggesting that the expression of endogenous ARCD-1 is below the detection limit of these reagents (data not shown).
In conclusion, the current results demonstrate that ARCD-1 is an authentic cytidine deaminase whose in vitro enzymatic kinetics are similar to those of apobec-1. ARCD-1 binds to but does not catalyze C to U editing of apoB RNA; rather, it inhibits apobec-1 in a dose-dependent manner. Together, these data suggest that ARCD-1 may function in a dominant negative fashion to constrain C to U editing, although its role in the regulation of apoB RNA editing remains to be determined. Further studies are necessary to determine whether ARCD-1 is an authentic component of the apoB RNA editing holoenzyme. In addition, the observation that ARCD-1 expression is ubiquitous raises the question of its role in other tissues. In this regard, ARCD-1 is only the second example of a eukaryotic protein that encodes both enzymatic cytidine deaminase and RNA-binding activities, albeit of low specificity in regard to this latter function (2) . However, it should be emphasized that neither phorbolin nor AID (other recently described homologues of apobec-1) expresses RNA binding activity (24, 27) . We suspect that the target transcript (if any) of ARCD-1 would most likely be expressed in one of the tissues where ARCD-1 is highly expressed, namely, cardiac and skeletal muscle. These and other questions concerning the function of this gene product may be the focus of future reports.
